Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study
- 1.1k Downloads
Liraglutide can modulate insulin secretion by directly stimulating beta cells or indirectly through weight loss and enhanced insulin sensitivity. Recently, we showed that liraglutide treatment in overweight individuals with prediabetes (impaired fasting glucose and/or impaired glucose tolerance) led to greater weight loss (−7.7% vs −3.9%) and improvement in insulin resistance compared with placebo. The current study evaluates the effects on beta cell function of weight loss augmented by liraglutide compared with weight loss alone.
This was a parallel, randomised study conducted in a single academic centre. Both participants and study administrators were blinded to treatment assignment. Individuals who were 40–70 years old, overweight (BMI 27–40 kg/m2) and with prediabetes were randomised (via a computerised system) to receive liraglutide (n = 35) or matching placebo (n = 33), and 49 participants were analysed. All were instructed to follow an energy-restricted diet. Primary outcome was insulin secretory function, which was evaluated in response to graded infusions of glucose and day-long mixed meals.
Liraglutide treatment (n = 24) significantly (p ≤ 0.03) increased the insulin secretion rate (% mean change [95% CI]; 21% [12, 31] vs −4% [−11, 3]) and pancreatic beta cell sensitivity to intravenous glucose (229% [161, 276] vs −0.5% (−15, 14]), and decreased insulin clearance rate (−3.5% [−11, 4] vs 8.2 [0.2, 16]) as compared with placebo (n = 25). The liraglutide-treated group also had significantly (p ≤ 0.03) lower day-long glucose (−8.2% [−11, −6] vs −0.1 [−3, 2]) and NEFA concentrations (−14 [−20, −8] vs −2.1 [−10, 6]) following mixed meals, whereas day-long insulin concentrations did not significantly differ as compared with placebo. In a multivariate regression analysis, weight loss was associated with a decrease in insulin secretion rate and day-long glucose and insulin concentrations in the placebo group (p ≤ 0.05), but there was no association with weight loss in the liraglutide group. The most common side effect of liraglutide was nausea.
A direct stimulatory effect on beta cell function was the predominant change in liraglutide-augmented weight loss. These changes appear to be independent of weight loss.
The study was funded by the ADA.
KeywordsBeta cell function Glucagon-like peptide 1 Insulin secretion Liraglutide Obesity Prediabetes Weight loss
Graded-glucose infusion test
Glucagon-like peptide 1
Impaired fasting glucose
Impaired glucose tolerance
Mixed-meal tolerance test
Steady-state plasma glucose
The authors thank P. Schaaf, the research dietitian, and the staff and nurses in the Stanford Clinical and Translational Research centre for their invaluable assistance with the study.
The study was funded by the ADA (7-09-NOVO-15 to GR). Liraglutide and matching placebo were provided by Novo Nordisk. The ADA and Novo Nordisk were not involved in the design or conduct of the study, the collection, management, analysis and interpretation of the data or the preparation, review or approval of the manuscript.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
SHK and GR conceptualised and designed the study and interpreted the analyses. SHK performed data analysis and drafted the manuscript. GR revised the manuscript for critical intellectual content. AL, DA, FA, CL, KG and VT helped acquire the data and edited the manuscript. All authors approved the final version of the manuscript. SHK is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.
- 8.Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC, Investigators DRAWRaRMD (2010) Effect of Rosiglitazone and Ramipril on β-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care 33:608–613Google Scholar
- 9.Degn KB, Juhl CB, Sturis J et al (2004) One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53:1187–1194PubMedCrossRefGoogle Scholar
- 20.American Diabetes Association (2013) Standards of medical care in diabetes–2013. Diabetes Care 36(Suppl 1):S11–S66Google Scholar